MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Initial Success Shown In Second Phase Of Oragenics, Inc. (OGEN) Collaboration's Lantibiotics Project 0 comments
    Aug 26, 2013 2:40 PM | about stocks: OGEN

    Through the exclusive channel collaboration (NYSE:ECC) between Oragenics and synthetic biology company Intrexon, preliminary experiments are demonstrating that a genetically modified (NYSE:GM) host can be engineered to produce improved titers of MU1140 - OGEN's lead compound - progressing toward the commercial production of lantibiotics (a novel class of broad spectrum antibiotics).

    Two new methods of purifying MU1140 have also been uncovered through the collaboration, resulting in higher purity and yields of the compound. The next step will be using the GM host to produce analogs of MU1140 that are anticipated to show improved antimicrobial, chemical, and pharmacological properties - with an objective of building a comprehensive antibiotic pipeline against a variety of life-threatening indications.

    Due to low titers and purification issues, it was originally thought that producing MU1140 by fermentation would not be commercially viable. But the Oragenics-Intrexon ECC has shown that applying specific expertise in key areas may allow a feasible commercial strategy and ultimately bring these drugs into human clinical studies. The Oragenics R&D team, which includes respected antibiotic commercialization experts, is currently designing preclinical development plans.

    Oragenics and Intrexon entered into an ECC in June of 2012 to develop and commercialize lantibiotics for the treatment of infectious diseases. The companies are now pursuing a pipeline of new lantibiotics that are especially active against various Gram positive bacteria that are resistant to drugs of last resort.

    For more information, visit oragenics.com

    Please see disclaimer on the MissionIR website

    www.missionir.com/disclaimer.html

    Stocks: OGEN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.